Overview
-
As of 2022, there are 1,089 bio companies in South Korea; as for bio-related sites (in order of factories > research centers > headquarters),
358 sites are located in Gyeonggi-do and 266 in Seoul, indicating that the majority of them are distributed in the Seoul/Gyeonggi area.
Gyeonggi-do | 358 | Jeollanam-do | 34 | Busan | 13 |
---|---|---|---|---|---|
Seoul | 266 | Jeollabuk-do | 32 | Ulsan | 9 |
Daejeon | 87 | Daegu | 32 | Gwangju | 8 |
Chungcheongbuk-do | 85 | Gyeongsangnam-do | 28 | Jeju | 7 |
Gangwon-do | 45 | Gyeongsangbuk-do | 25 | Sejong | 4 |
Chungcheongnam-do | 41 | Incheon | 15 | - | - |
- As of 2022, the number of employees working in 1,089 domestic bio companies
is 61,152, which represents an increase of 4,434 compared to that in 2021.
- Bioindustry manpower consists of 19,325 (31.6%) research personnel, 18,828(30.8%), production personnel and 22,999 (37.6%) other personnel, who are involved in sales and management.
- In 2022, the total investment cost of bioindustry companies for one year was KRW 13,267 billion, and the total investment cost in the bioindustry sector was KRW 4,126 billion (31.1% of the total investment cost).
- The R&D cost was KRW 2,385 billion and the facility investment cost was KRW 1,740 billion.
- As of 2022, Bioindustry sales volume was KRW 23,466 billion, of which domestic sales accounted for KRW 9,947 billion (42.4%) and exports for KRW 13,519 billion (57.6%).
- The domestic market size was KRW 14,193 billion, of which imports accounted for KRW 4,247 billion (29.9%), excluding domestic sales of KRW 9,947 billion (70.1%)